IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Biosciences (Nasdaq: IDYA) priced an underwritten public offering of common stock and pre-funded warrants.

Rhea-AI Summary

IDEAYA Biosciences (Nasdaq: IDYA) priced an underwritten public offering of common stock and pre-funded warrants. The company will sell 5,555,556 shares and pre-funded warrants for 5,555,576 shares at $27.00 and $26.9999, respectively, to raise approximately $300 million in gross proceeds.

The offering, including a 30-day option for underwriters to buy up to 1,666,669 additional shares, is expected to close on or about June 10, 2026, subject to customary conditions.

Positive

• Expected gross proceeds of approximately $300 million before expenses
• Flexible structure using both common stock and pre-funded warrants
• 30-day underwriter option for up to 1,666,669 additional shares

Negative

• Issuance of 5,555,556 new shares creates immediate shareholder dilution
• Pre-funded warrants for 5,555,576 shares add potential future dilution
• Underwriters’ option could further increase share count if exercised

Argus Jun 9 session

-10.83% close to close Open Argus

Details

News Market Reaction – IDYA

On Jun 9, the first trading day after this news, IDYA closed 10.83% below the previous close.

Data tracked by StockTitan Argus for the Jun 9 session.

Key Figures

Common shares offered: 5,555,556 shares Pre-funded warrants offered: 5,555,576 warrants Common share offering price: $27.00 per share +5 more

Common shares offered

5,555,556 shares

Underwritten public offering of common stock

Pre-funded warrants offered

5,555,576 warrants

Pre-funded warrants to purchase common stock

Common share offering price

$27.00 per share

Public offering price before underwriting discounts

Pre-funded warrant price

$26.9999 per warrant

Public offering price before underwriting discounts

Warrant exercise price

$0.0001 per share

Exercise price of pre-funded warrants

Underwriter option shares

1,666,669 shares

30-day option for additional common stock

Gross proceeds (offering)

$300.0 million

Expected aggregate gross proceeds, excluding warrant exercise

Shares outstanding

87,856,154 shares

Common stock outstanding as of March 31, 2026 (424B5)

Previous Offering Reports

3 past events · Latest: Jul 11

Same Type 3 events

1. Jul 11

   Offering closing

   24h Move

   +1.0%

   Closed prior follow-on offering including full exercise of underwriters’ option.

2. Jul 09

   Offering pricing

   24h Move

   -3.4%

   Priced underwritten offering of shares and pre-funded warrants at $35.00.

3. Jul 09

   Proposed offering

   24h Move

   -3.4%

   Announced proposed public offering of up to $200M plus $30M option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, form s-3, +2 more

6 terms

pre-funded warrants financial

"IDEAYA is selling 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"announced the pricing of an underwritten public offering of common stock and pre-funded warrants."

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to an automatically effective shelf registration statement on Form S-3..."

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed..."

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"only by means of a written prospectus and prospectus supplement that form a part of the registration statement..."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

registration statement regulatory

"prospectus and prospectus supplement that form a part of the registration statement..."

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,555,556 shares of common stock and pre-funded warrants to purchase 5,555,576 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $27.00 per share, before underwriting discounts and commissions, and the pre-funded warrants are being sold at a public offering price of $26.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 1,666,669 shares of its common stock at the public offering price per share, before underwriting discounts and commissions. The aggregate gross proceeds to IDEAYA from this offering are expected to be approximately $300.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. The offering is expected to close on or about June 10, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Jefferies, TD Cowen, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for this offering.

The securities described above are being offered by IDEAYA pursuant to an automatically effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission, or the SEC. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, copies of which may be obtained, when available, by request from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities, by mail at TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; UBS Investment Bank, by mail at UBS Securities LLC, 11 Madison Avenue, New York, NY 10010, Attention: Equity Syndicate, or by email at ol-prospectus-request@ubs.com; or Cantor, by mail at Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation statements regarding the expected closing of the public offering, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management's current expectations, assumptions and beliefs and involve substantial risks and uncertainties that could cause actual results, including, but not limited to, those related to IDEAYA's clinical programs, commercial activities, and performance and/or achievements, to differ significantly and/or materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, the uncertainties inherent in the drug development process, including the process of designing and conducting preclinical and clinical trials, enrollment rates, safety outcomes, efficacy results, regulatory interactions and decisions, and the ability to translate preclinical findings into clinical benefit, manufacturing and supply risks, competition, changes in standard of care, the timing and success of commercialization efforts, the outcome of collaborations and licensing arrangements, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect IDEAYA's ability to complete the offering. IDEAYA undertakes no obligation to update or revise any forward-looking statements. A further description of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, are in IDEAYA's filings with the SEC, including IDEAYA's most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the period ended March 31, 2026, any current and periodic reports filed with the SEC, and preliminary prospectus supplement related to the proposed public offering.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-pricing-of-300-million-offering-of-common-stock-and-pre-funded-warrants-302794628.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEAYA Biosciences (NASDAQ: IDYA) announce about its June 2026 stock offering?

IDEAYA announced an underwritten public offering of common stock and pre-funded warrants, expected to raise about $300 million in gross proceeds. According to IDEAYA, the deal combines newly issued shares and pre-funded warrants, with a possible additional allotment for underwriters.

What is the offering price for IDEAYA (IDYA) common stock and pre-funded warrants in June 2026?

IDEAYA priced its common stock at $27.00 per share and pre-funded warrants at $26.9999 each. According to IDEAYA, the pre-funded warrants carry a $0.0001 per-share exercise price, effectively aligning them with the common stock price for investors.

How much money will IDEAYA (IDYA) raise from its 2026 stock and warrant offering?

IDEAYA expects gross proceeds of approximately $300 million from the offering, before underwriting discounts, commissions, and expenses. According to IDEAYA, this estimate excludes any proceeds from pre-funded warrant exercises and from the underwriters’ 30-day option for additional shares.

How many shares are included in the IDEAYA (IDYA) June 2026 equity offering?

IDEAYA is selling 5,555,556 shares of common stock plus pre-funded warrants for 5,555,576 additional shares. According to IDEAYA, underwriters also have a 30-day option to purchase up to 1,666,669 more shares at the public offering price, excluding fees.

When is the IDEAYA (IDYA) June 2026 stock offering expected to close?

The IDEAYA offering is expected to close on or about June 10, 2026, subject to customary closing conditions. According to IDEAYA, completion depends on standard requirements typically seen in underwritten public equity offerings in U.S. capital markets.

What does the IDEAYA (IDYA) equity offering mean for existing shareholders?

The offering increases IDEAYA’s share count and introduces pre-funded warrants, resulting in dilution for existing shareholders. According to IDEAYA, 5,555,556 new shares and 5,555,576 warrant shares will be issued, with potential additional shares through the underwriters’ option.